New Two-Drug attack on ALS brain inflammation begins human testing
NCT ID NCT07321860
Summary
This study is testing whether combining two drugs, galunisertib and nerandomilast, can slow the progression of ALS in patients who have a specific biomarker called GREM2. The drugs aim to reduce harmful inflammation and scarring in the nervous system. The trial will enroll 60 adults with relatively recent ALS diagnoses to see if the treatment changes disease-related biomarkers and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.